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Abstract
Background: The term endothelial progenitor cells (EPCs) is currently used to refer to cell populations which are quite 
dissimilar in terms of biological properties. This study provides a detailed molecular fingerprint for two EPC subtypes: 
early EPCs (eEPCs) and outgrowth endothelial cells (OECs).
Methods: Human blood-derived eEPCs and OECs were characterised by using genome-wide transcriptional profiling, 
2D protein electrophoresis, and electron microscopy. Comparative analysis at the transcript and protein level included 
monocytes and mature endothelial cells as reference cell types.
Results: Our data show that eEPCs and OECs have strikingly different gene expression signatures. Many highly 
expressed transcripts in eEPCs are haematopoietic specific (RUNX1, WAS, LYN) with links to immunity and inflammation 
(TLRs, CD14, HLAs), whereas many transcripts involved in vascular development and angiogenesis-related signalling 
pathways (Tie2, eNOS, Ephrins) are highly expressed in OECs. Comparative analysis with monocytes and mature 
endothelial cells clusters eEPCs with monocytes, while OECs segment with endothelial cells. Similarly, proteomic 
analysis revealed that 90% of spots identified by 2-D gel analysis are common between OECs and endothelial cells 
while eEPCs share 77% with monocytes. In line with the expression pattern of caveolins and cadherins identified by 
microarray analysis, ultrastructural evaluation highlighted the presence of caveolae and adherens junctions only in 
OECs.
Conclusions: This study provides evidence that eEPCs are haematopoietic cells with a molecular phenotype linked to 
monocytes; whereas OECs exhibit commitment to the endothelial lineage. These findings indicate that OECs might be 
an attractive cell candidate for inducing therapeutic angiogenesis, while eEPC should be used with caution because of 
their monocytic nature.
Background
Endothelial Progenitor Cells (EPCs) are a minor popula-
tion of mononuclear cells circulating in peripheral blood
[1]. Although rare in comparison to other blood cells,
EPCs are capable of facilitating vascular repair in differ-
ent ischaemic tissues, therefore they have been regarded
as promising candidates for inducing therapeutic angio-
genesis in multiple diseases such as acute myocardial
infarction, unstable angina, stroke, diabetic microvascul-
opathies, pulmonary arterial hypertension, atherosclero-
sis, and ischaemic retinopathies [2-6].
EPCs are classically described as cells expressing a
combination of an endothelial marker (VEGFR2) and a
progenitor marker (CD34/CD133), however there is con-
siderable debate surrounding this definition, because
none of these markers are fully specific [7,8]. It has been
reported that CD34+ CD133+ VEGFR2+ cells are hae-
matopoietic and may not actually be true EPCs [9].
Indeed, a methodological comparison of six flow cyto-
metric approaches for EPC quantification using CD34
and VEGFR2 markers has demonstrated only poor to
moderate agreement between methods [10].
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eral or umbilical cord blood utilizes in vitro culture and
this consistently produces two distinct EPC subtypes
which have been named as early EPCs (eEPCs) and Out-
growth endothelial cells (OECs) [11]. OECs are also
known as endothelial colony-forming cells (ECFCs)[12]
or late EPCs because of their late appearance in culture.
Although clear differences have been shown between
these two endothelial progenitors, there is still concern
surrounding their nature [8], and debate about whether
these putative EPCs represent the 'bona fide' EPC [7]. It
has been previously demonstrated that both subsets con-
tribute to angiogenesis, but through different mecha-
nisms. eEPCs act in a paracrine manner, while OECs
directly incorporate into resident vasculature [13,14]. A
range of pre-clinical and clinical studies using EPCs have
yielded inconsistent outcomes in terms of therapeutic
benefit, implying that a precise EPC definition needs to
be elucidated [15]. Moreover, many clinical trials still use
very heterogeneous populations of cells such as unfrac-
tionated bone marrow or freshly isolated CD34 + cells
[2,4]. Clearly, an accurate EPC definition based on a
broad range of molecular characteristics is needed. If
sub-populations could be precisely characterized, this
would facilitate the use of the most appropriate cell ther-
apy in future clinical trials [16]. The aim of this study was
to provide a thorough, unbiased analysis of the pheno-
type of the two EPC subsets isolated in vitro; eEPCs and
OECs. This was achieved using combined transcriptomic
and proteomic analysis to establish a highly detailed
molecular fingerprint of these important endothelial pro-
genitors.
Methods
Cell Isolation and culture
This study was approved by the Office for Research Eth-
ics Committees Northern Ireland (ORECNI 08/NIR02/
20). EPCs were isolated from human peripheral blood
(PB) and umbilical cord blood (CB). Fresh human PB (40
mls) was obtained under full ethical approval from three
female volunteer subjects aged 25-35, non-smokers, not
receiving any medication and without any clinical diag-
nosis; while CB-derived mononuclear cells (MNCs) were
purchased from AllCells LLC (California, USA). MNCs
were isolated from PB by density gradient centrifugation.
To obtain eEPCs, MNCs were seeded at a density of 2 ×
106 cells/ml onto fibronectin coated petri dishes and cul-
tured in complete EBM-2 MV medium (Lonza Ltd.,
Slough, UK) that contained hEGF, VEGF, hFGF-B, R3-
IGF-1 and was supplemented with 10% FBS. OECs were
obtained by seeding MNCs onto collagen coated wells at
a density of 1 × 107 cells/ml using complete EBM-2
medium with the same supplements as described above
[17]. Monocytes were isolated from peripheral blood by
positive selection using CD14 MicroBeads and an
autoMACs separator (Miltenyi Biotec, Bergisch Glad-
bach, Germany). Human dermal microvascular endothe-
lial cells (DMECs) were purchased from PromoCell
GmbH (Heidelberg, Germany) and cultured in endothe-
lial cell basal medium MV (Promocell).
RNA extraction and microarray analysis
Total RNA was extracted using an RNAqueous kit
(Ambion, Cambridgeshire, UK). 1 μg of RNA from each
cell sample was labelled and hybridised to an Illumina
WG-6 v3.0 Expression Beadchip. Samples included in the
array analysis were: 3 biological replicates for PB-derived
eEPCs and OECs, 3 technical replicates for CB-derived
eEPCs and OECs, and single samples for controls DMECs
and monocytes. Gene expression data obtained from Illu-
mina Beadstudio was normalised using 'R' bioconductor
with 'lumi' package [18]. Data was processed and analy-
sed using the National Institute on Aging (NIA) array,
The Database for Annotation, Visualisation and Inte-
grated Discovery (DAVID), GenePattern, and visual anay-
sis tool (visANT) software.
Conventional RT-PCR
RT was performed with 500 ng of RNA using random
hexamers and Superscript II (Invitrogen, Paisley, UK).
Primers were designed using Primer BLAST and tested
with AmplifX software. Primer sequences are shown in
Additional File 1 Table S1. Conventional RT-PCR was
performed in a 30 μl reaction volume containing 1 μl of
cDNA, 0.2 μM sense and anti-sense primers designed for
the particular gene of interest (Invitrogen), 1× PCR buffer
(Invitrogen), 10 mM dNTP mix (Roche, Mannheim, Ger-
many), and 1 μl DNA polymerase (Invitrogen). PCR was
performed for 30 cycles using a thermocycler (ABI 2720,
Applied Biosystems, Foster City, CA). PCR products were
resolved by 2% agarose gel electrophoresis.
Real time RT-PCR
Quantitative real time RT-PCR reactions were performed
in a 10 μl volume containing 2 μl of 1:15 diluted cDNA
template, 0.5 μM of sense and anti-sense primers (Invit-
rogen), and 5 μl of SYBR green mastermix (Qiagen, Craw-
ley, UK). PCR was performed for 45 cycles with
denaturation at 94°C for 15 seconds, annealing at 55°C for
30 seconds, and extension at 72°C for 30 seconds using a
LightCycler 480 (Roche). Standard curves for quantifica-
tion of PCR products were constructed using serial dilu-
tions of pooled cDNA.
Protein Extraction and 2D gel electrophoresis
Protein was extracted by lysing cells in 9 M urea, 2 M
thiourea, 4% CHAPS buffer. 7 cm immobilized 4-7 pH
gradient (IPG) strips (GE Healthcare Life Sciences, Buck-
inghamshire, UK) were rehydrated overnight at room
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tein. Isoelectric focusing (IEF) was performed on a Phar-
macia Biotech Multiphor II tray in a stepwise fashion
(Step 1: 500 volts, 1 mA, 5 watts(W) and 5 volt hours
(Vhrs); step 2: 3500 volts, 1 mA, 5 W and 5200 Vhrs; and
step 3: 3000 volts, 1 mA, 5 W and 3500 Vhrs). After IEF,
reduction and alkylation of thiol groups was performed
by immersing strips in equilibration buffer containing 10
mg/ml dithiothreitol (DTT) for 15 minutes, and then 27
mg/ml of iodoacetamide (Sigma-Aldrich, UK) for 15 min-
utes, respectively. Equilibrated strips were placed hori-
zontally on top of NuPAGE 4-12% Bis-Tris gels
(Invitrogen) and secured in place by covering it with 0.5%
agarose gel (w/v) made up in running buffer and contain-
ing trace amounts of bromophenol blue. Electrophoresis
was performed starting at 50 V for 30 minutes, then 100
V for up to 2 hours. Gels were fixed for 1 hour in 40%
methanol (v/v), 7% acetic acid (v/v) and immersed in Col-
loidal coomassie solution (Sigma) overnight at room tem-
perature with gentle agitation. Gels were de-stained with
10% acetic acid (v/v), 1% glycerol (v/v) de-stain solution,
and scanned using an Odyssey imaging system (Licor
Biosciences, UK). Image analysis was performed with
Progenesis PG220 software (Nonlinear Dynamics Ltd.,
Newcastle upon Tyne, UK).
Electron microscopy
To preserve apico-basal polarity and architecture of cell
monolayers, cells were grown on glass coverslips and
fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer at 4°C overnight. After post-fixation in 1% osmium
tetroxide, cells were dehydrated with increasing alcohol
concentrations and embedded in Spurr resin. Ultrathin
sections for both horizontal and vertical planes were pre-
pared using an ultramicrotome, placed on copper grids
(Agar Scientific Ltd, UK), stained with uranyl acetate and
lead citrate, and examined using a JEOL 100 CX trans-
mission electron microscope.
Results
Human peripheral blood-derived eEPCs and OECs have 
distinct genomic profiles
eEPCs and OECs were isolated from human peripheral
blood according to established protocols. Each endothe-
lial progenitor type exhibited distinctive and homoge-
neous cell morphology in vitro: eEPCs appeared as
spindle-shaped cells (Additional File 1 Figure S1A) that
demonstrated a low proliferative potential and no ten-
dency to form contiguous colonies. By contrast, OECs
formed confluent cobblestone-shaped monolayers (Addi-
tional File 1 Figure S1B) and showed high proliferative
potential. Respective immunophenotypes using flow
cytometry demonstrated eEPCs express haematopoietic
markers CD45 and CD14, while OECs express endothe-
lial markers CD146 and CD105 (R. M. and A. S., manu-
script submitted 05/10/09). Total RNA was extracted
from 7 day-old eEPC cultures and early passage OECs.
Three biological replicates per EPC subtype were used for
transcriptome analysis using Illumina WG-6 v3.0 expres-
sion beadchips to assay more than 48000 transcripts,
including 25,400 well characterised human transcripts
and additional confirmed mRNAs in the UniGene data-
base. Paired comparisons using National Institute on
Aging (NIA) array analysis determined a correlation
greater than 0.98 for eEPC biological replicates, and
greater than 0.97 for OEC replicates (Additional File 1
Table S2). However, when comparing eEPCs and OECs,
correlation decreased to less than 0.77, demonstrating
that these two EPC types differ significantly at the molec-
ular level. Further statistical assessment for genes
enriched at least 2 fold with a false discovery rate of 0.01
showed minimal differences (<25 transcripts) between
biological replicates belonging to the same EPC subtype
(Figure 1A, B), however scatter plots for eEPCs vs. OECs
distinguished 2560 transcripts significantly more highly
expressed in eEPCs, and 2674 transcripts more highly
expressed on OECs (Figure 1C). Lists of the top 20 differ-
entially expressed transcripts in eEPCs/OECs are shown
in Table 1 and 2, respectively. The full microarray data is
deposited in the NCBI Gene Expression Omnibus (GEO)
available at http://www.ncbi.nlm.nih.gov/geo with Acces-
sion number GSE20283.
Principal component analysis (PCA) further demon-
strated the differences between the mRNA expression
profiles of eEPCs and OECs. Using a single component
(PC1) it was possible to separate samples into two groups;
one containing the three eEPC biological replicates with a
high PC1 value, and other group with the three OEC bio-
logical replicates showing a low PC1 value (Figure 1D).
The PCA biplot analysis highlighted some differentially
expressed genes for each group; eEPC genes included
HLA-DRA, CD36, CD14, and complement 1QC, while
OEC genes comprised caveolin1, VE-cadherin, CD34,
and endothelial specific molecule 1, among others (Figure
1E).
In order to gain an insight into the biological meaning
behind these long lists of genes, the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID)
bioinformatics software was used to assess the top 400
genes differentially expressed in each cell type. The genes
preferentially expressed by eEPCs were enriched for
those involved in immune response and inflammation,
while OECs expressed genes involved in development
and angiogenesis (Additional File 1 Table S3). Further-
more we used protein network analysis (interactome) for
assessment of genome-wide transcriptomics data. This
assumes that the transcriptome profile is a fair, albeit
incomplete representation of the proteome. Interactome
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ray experiments in a broader biological context, thus
highlighting molecular pathways characteristic of each
cell type. Interactome analysis for over 1700 differentially
expressed transcripts using the integrative visual analysis
tool for biological networks and pathways (visANT) cor-
roborated these findings by showing angiogenesis-related
gene networks such as Tie2, eNOS, and Ephrin signalling
in OECs (Figure 2A) and inflammation networks includ-
ing TLRs, HLAs and CYBs in eEPCs. It also demon-
strated an abundance of haematopoietic specific elements
such as RUNX, WAS, PTPN6, HCLS1 in eEPCs (Figure
2B).
To validate gene microarray results, conventional RT-
PCR and real time RT-PCR were performed. According
to our previous transcript profiling, three highly
expressed transcripts for each EPC type were chosen;
HLA-DRA, lysozyme, and CD14 for eEPCs, and
caveolin1, VE-cadherin, and vWF for OECs. In order to
verify that transcriptome analysis could be generalized,
eEPCs and OECs from different donors were used for
PCR experiments. Conventional RT-PCR at 30 cycles
revealed marked higher expression of HLA-DRA, LYZ,
and CD14 transcripts in eEPCs, while CAV1, VE-cad-
herin, and vWF transcripts were only present in OECs
(Figure 3A). Similarly, qRT-PCR results were also consis-
tent with microarray results (Figure 3B, C), indicating a
good correlation between the two methods, however, as
commonly reported greater fold gene expression changes
were observed higher (by 1.4-5.6 times) with qRT-PCR
than in gene microarray experiments. The microarray
and qRT-PCR transcriptome data demonstrate that
eEPCs and OECs represent two dissimilar types of
endothelial progenitors.
OECs mRNA fingerprint closely resembles endothelial cells, 
eEPCs resemble monocytes
Discrepancies exist in the published literature on whether
EPCs have monocytic features [19] or not. There is evi-
dence to demonstrate CD14+ cells can generate EPCs
Table 1: Identification of differentially expressed transcripts between PB.OECs and eEPCs: Top 20 transcripts higher in 
eEPCs.
Gene Annotation* Symbol Fold Change
Complement component 1, q 
subcomponent, C chain
C1QC 257.10
TYRO protein tyrosine kinase binding protein TYROBP 250.38
CD163 molecule CD163 244.85
Secreted phosphoprotein 1 SPP1 239.94
Fc fragment of IgE FCER1G 222.58
Lymphocyte cytosolic protein 1 LCP1 220.90
Glycoprotein nmb, transcript variant B GPNMB 209.85
ADAM-like, decysin 1 ADAMDEC1 206.59
Major histocompatibility complex, class II, 
DR alpha
HLA-DRA 194.40
Membrane-spanning 4-domains, subfamily 
A, member 6A
MS4A6A 193.46
Major histocompatibility complex, class II, 
DM alpha
HLA-DMA 183.40
Selenoprotein P, plasma 1 SEPP1 181.55
Apolipoprotein E APOE 176.85
CD14 molecule CD14 176.01
Matrix metallopeptidase 9 MMP9 173.02
Transmembrane 4L six family member 19 TM4SF19 170.22
Colony stimulating factor 1 receptor CSF1R 164.51
S100 calcium binding protein A9 S100A9 158.93
Matrix metallopeptidase 7 MMP7 157.78
Integrin beta 2, lymphocyte antigen 1 ITGB2 156.86
*Immune response-related genes highlighted in bold.
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other hand, it has also been suggested that blood mono-
cytes only mimic endothelial progenitors and do not
directly contribute to vascular network formation [22].
Furthermore, differentially expressed genes described
above (Figures 1 and 2, Tables 1 and 2) suggest monocytic
and endothelial characteristics for eEPCs and OECs
respectively. Therefore, to elucidate and differentiate the
expressed phenotypes of endothelial progenitors, eEPC
and OEC transcriptomes were directly compared with
monocytes and endothelial cells. Monocytes were iso-
lated from fresh peripheral blood by CD14 positive selec-
tion using a magnetic cell sorter and human dermal
microvascular endothelial cells (DMECs) were chosen as
mature endothelial cells. Total RNA from these two cell
types was extracted and used as comparator transcrip-
tomes. CB-derived as opposed to PB-derived eEPCs and
OECs were also included in transcriptomic analysis as it
has been suggested that foetal blood may represent a
richer EPC source than adult peripheral blood [23,24].
Hierarchical clustering of 21,825 expressed transcripts
out of the 48,000 present on the Illumina microarray
shows two main branches: one grouping eEPCs with
monocytes (1,053 transcripts in common) and the other
branch composed of OECs and DMECs (1,269 common
transcripts) (Figure 4A). eEPCs from adult PB and foetal
CB clustered together and only 483 eEPC-specific tran-
scripts distinguished these cells from monocytes. Inter-
estingly, PB-derived OECs clustered closer to DMECs
than to their CB-derived counterparts. Heat maps gener-
ated using GenePattern software for the top 30 distinctly
expressed transcripts in each EPC subtype show expres-
sion patterns at the gene level consistent with hierarchical
cluster analysis (Figure 4B, C). As expected, biological
replicates of the same EPC type had very similar gene
expression profiles. Furthermore, eEPC gene expression
patterns partially matched monocytes, and OECs were
closely linked to DMECs. Although eEPCs were grouped
with monocytes, some subtle mRNA transcription differ-
ences were identified such as complement components
(C1QC, C1QB), matrix metalloproteinases (MMP9,
MMP7, ADAMDEC1) and osteopontin (SPP1) which
were higher in eEPCs than in monocytes. This transcrip-
tome analysis of endothelial progenitors, mature
endothelial cells and monocytes has added novel infor-
mation and evidence to support the idea that OECs are
Table 2: Identification of differentially expressed transcripts between PB.OECs and eEPCs: Top 20 transcripts higher in 
OECs.
Gene Annotation* Symbol Fold Change
Caveolin 1 CAV1 216.27
EGF-containing fibulin-like extracellular 
matrix protein 1
EFEMP1 199.8
Procollagen-lysine, transcript variant 2 PLOD2 143.52
Claudin 11 CLDN11 142.59
Four and a half LIM domains 2 FHL2 120.11
Connective tissue growth factor CTGF 106.24
Guanine nucleotide binding protein GNG11 106.56
Biglycan BGN 102.54
VE-Cadherin CDH5 100.55
Transmembrane 4L six family member 1 TM4SF1 93.95
Matrix metallopeptidase 1 MMP1 89.91
S100 calcium binding protein A16 S100A16 88.25
Cysteine-rich, angiogenic inducer, 61 CYR61 88.06
Claudin 5 CLDN5 79.78
C-type lectin domain family 14, member A CLEC14A 79.41
Homo sapiens dickkopf homolog 1 DKK1 76.98
Homo sapiens PDZ and LIM domain 1 PDLIM1 71.12
Endothelial cell-specific molecule 1 ESM1 69.92
SRY (sex determining region Y)-box 18 SOX18 69.18
Laminin, alpha 5 LAMA5 61.16
*Endothelial cell -related genes highlighted in bold.
Medina et al. BMC Medical Genomics 2010, 3:18
http://www.biomedcentral.com/1755-8794/3/18
Page 6 of 13progenitors committed to the endothelial lineage; in con-
trast, eEPCs represent a distinct cell type which resem-
bles monocytes.
Comparative proteomic analysis of EPCs, monocytes and 
mature endothelial cells
To corroborate the transcriptomics outcomes at the pro-
tein level, 2D-PAGE was used to investigate proteomes of
each EPC subtype. Protein lysates from monocytes and
DMECs were also included to enable comparisons with
EPCs. Coomassie blue staining of 2D gels revealed 156
protein spots for eEPCs, 126 for OECs, 183 for DMECs,
and 199 for monocytes (Figure 5A). A total of 298 distinct
spots were identified in all four groups and 70 spots
among them were common to all groups (Additional File
1 Figure S2). For comparative analysis, gels were arbi-
Figure 1 Peripheral blood-derived eEPC and OECs have distinctive transcriptomes. Normalised data from Illumina WG-6 v3.0 Expression Bead-
chip were imported into NIA array for analysis. Numbers of upregulated transcripts are shown in red and downregulated transcripts in green. There 
were minimal differences (<50 transcripts) among technical replicates as shown by the log-ratio chart for pairwise comparison of eEPC replicates(A), 
and the log-ratio chart for pairwise comparison of OEC replicates(B); however there were extensive differences (> 5000 differentially expressed tran-
scripts) when eEPCs were compared to OECs as shown by the log-ratio chart for pairwise comparison of eEPCs vs. OECs(C). Prinicipal component anal-
ysis (PCA) segregates eEPCs from OECs(D) using one single component (PC1). Biplot analysis on PCA graph identifies transcripts specifically expressed 
in each EPC subtype(E).
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Figure 2 Transcriptome-based interactome analysis reveals that eEPCs express haematopoietic transcripts and OECs express endothelial 
transcripts. Differentially expressed transcripts were imported into visANT software to create gene networks. Diagrams show nodes representing 
genes, lines indicate interactions between proteins, and boxes denote functional categories. (A) eEPC interactome network, nodes in red are primarily 
haematopoietic. (B) OEC interactome network, nodes in red are highly expressed in endothelial cells.
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paired to identify common spots that appeared in a
merged colour (green) as shown in Figure 5B. Quantifica-
tion revealed that eEPCs shared 120 spots with mono-
cytes, indicating 77% of the eEPC protein spot profile is
similar to monocytes (Figure 5C). Of note, OECs demon-
strated 113 spots in common with DMECs (representa-
tive of 90% of the entire protein profile) (Figure 5D and
Additional File 1 Table S4). Although we did not charac-
terise protein spots by mass spectrometry, there were 8
spots specific for OECs and 21 spots specific for eEPCs
(Additional File 1 Figure S3). These spots might represent
important cellular markers for these progenitors. Com-
parisons by 2D gel overlapping is also possible in a
motion picture format that flicks from sample gel to com-
parator gel allowing easy visual recognition of similarities
and differences (Additional Files 2, 3, 4 and 5). These
findings demonstrate that the OEC protein profile is
closely related to endothelial cells; and the eEPC protein
signature is very similar to monocytes.
OECs have characteristic endothelial ultrastructural 
features
Morphological assessment by electron microscopy
showed that eEPC (Figure 6A) are very different from
OECs (Figure 6B) with only the latter showing apico-
basal polarity. OEC microarray data revealed high expres-
sion of VE-cadherin, claudin 11, claudin 5, caveolin 1 and
caveolin 2 which was indicative of the presence of cell-cell
specialized junctions and caveolae organelles. Ultrastruc-
tural examination of OECs revealed the presence of adhe-
rens junction-like cell-cell contacts identified as discrete
areas of electron-dense material on the cytoplasmic face
and particles within the intercellular space of 15 nm (Fig-
ure 6C). Furthermore, OECs showed abundant flask-like
invaginations of the plasma membrane with a diameter of
30-80 nm (Figure 6D). These caveolae occurred both as
Figure 3 Expression of characteristic eEPC and OEC genes determined by RT-PCR. (A) Expression of mRNAs distinctive for eEPCs and OECs de-
termined by semiquantitative PCR: eEPC highly expressed genes HLA-DRA, LYZ, and CD14; OECs highly expressed genes CAV1, VE-CAD, and VWF. (B) 
Quantitative real time PCR showing gene expression fold changes for the eEPC genes. (C) Quantitative real time PCR showing gene expression fold 
changes for the OEC genes. Error bars in B and C show mean ± SEM of three biological replicates for each EPC subtype.
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Figure 4 EPC gene signature relates to monocytes, while OECs are closely linked to endothelial cells. (A) Hierarchical clustering reveals two 
major branches: eEPCs are clustered together with monocytes, whilst OECs are grouped with DMECs. Distance represents the similarity of gene ex-
pression between different samples (the closer the more similar), and numbers in black indicate statistically significant number of transcripts that iden-
tify a cluster; numbers in blue are transcript cluster IDs: clusters 1-6 indicate specific transcripts for a cell type; clusters 7-10 indicate common transcripts 
for 2/3 cell types; and cluster 11 indicates transcripts present equally in all samples. (B) Heat map of top 30 highly expressed genes in eEPCs demon-
strating that eEPCs share a similar gene signature with monocytes. (C) Heat map of top 30 highly expressed genes in OECs indicates a high degree of 
correlation between OECs and DMECs.
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nor adherens junctions were observed on eEPCs, which
had multiple lysosome-like structures identified as intra-
cytoplasmic circular electron-dense vesicles of 100-300
nm (Figure 6A). This finding is consistent with the eEPC
transcriptome profile that indicated high expression of
lysosome enzymes such as lysozyme (LYZ), cathepsins
(CTSB, CTSD, CTSH, CTSL1), acid phosphatase (ACP2,
ACP5), acid lipase (LIPA), and β-glucoronidase (GUSB).
eEPCs also show nuclei containing extensive hetero-
chromatin and numerous plasma membrane projections
(Figure 6A).
Discussion
This study has revealed highly distinguishing transcript
signatures for eEPCs and OECs and clearly demonstrates
that these cells represent distinct EPC populations. We
show novel evidence based on transcriptomic-, pro-
teomic-, and ultrastructural- analysis to indicate that
eEPCs are haematopoietic cells with a monocytic-like
molecular profile, while the OEC molecular fingerprint
suggests close association to the endothelial lineage.
These findings suggest OECs as candidates to establish
cell therapies for ischaemic diseases because of their
unmistakable endothelial nature. On the other hand,
eEPCs should be used with caution because of their
monocytic nature and possible role enhancing tissue
inflammation.
In 1997, eEPCs were the first putative endothelial pro-
genitors isolated in vitro by culturing CD34+ VEGFR2+
mononuclear blood cells on fibronectin [25] and con-
firming a subsequent increase in expression of endothe-
lial cell-associated markers such as CD34, CD31,
VEGFR2, Tie2, and E-selectin. Later, this protocol was
Figure 5 Comparative proteome analysis of human DMECs, OECs, eEPCs, and monocytes. (A) Representative images of 2D gels showing pro-
tein spots distributed according to their molecular weight vertically; and isoelectric point horizontally from 4 to 7, right to left, respectively. (B) Com-
parative assessment by overlaying 2D gel images and matching spots. Common spots appear in green colour. Numbers in the bottom right corner 
show percentage of the progenitor cell proteome that matches the comparator cell type proteome. (C) Venn diagram indicating high overlap be-
tween DMECs and OECs proteomes. (D) Venn diagram showing quantification of similar spots between eEPCs and monocytes.
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the so-called CFU-Hill colony assay was developed as a
commercial kit to quantify EPCs [26]. In recent years, the
assertion that CD34+ VEGFR2+ cells are bona fide EPCs
has been challenged [9], and the cells growing as CFU-
Hill colonies have been genetically linked to primitive
haematopoietic cells [12] and suggested to be mainly
composed of monocytes and T cells [27]. Furthermore, it
has been recently demonstrated that monocytes can
acquire endothelial markers in vitro by uptake of platelet
microparticles, as a simple transfer of antigens CD31 and
vWF [28].
The comprehensive transcriptomic data obtained in the
current study strengthens the idea that eEPCs are indeed
haematopoietic cells with a typical monocytic phenotype.
Despite the fact that many studies have shown that eEPCs
can promote therapeutic neovascularisation in ischaemic
tissues [29], our data suggests that these cells should be
utilised for therapy with caution and consideration of the
underlying pathology they will treat. This is because the
eEPC transcriptome profile indicates a sub-population of
cells that are enriched for genes involved in inflammation
and immune responses. Therefore, if injected into a pro-
inflammatory microenvironment such as in ischaemic
diabetic tissues, it is possible they could serve to exacer-
bate the preexisting pathology [30].
The second putative EPC isolated in vitro was firstly
named endothelial outgrowth [31], also known as OECs,
ECFCs, and late outgrowth endothelial cells. These pro-
genitors were uniformly positive for endothelial markers
CD146, thrombomodulin, VEGFR2, VE-cadherin, CD31,
CD34, and typically showed greater proliferative poten-
tial than circulating endothelial cells. Our group along-
side others have established that OECs
immunophenotype consists of multiple endothelial mark-
ers and complete absence of haematopoietic markers
such as CD45 and CD14 [23,32]. The present study adds
strong new evidence to prove that OECs possess intrinsic
endothelial nature, as revealed in their transcriptome,
proteome, and ultrastructure. OECs have been described
to be directly involved in vascular repair by forming well-
perfused human neo-vessels when injected subcutane-
ously as matrigel plugs in immune-deficient mice [12,32]
and it is important to highlight that the OEC interactome
analysis identified essential vasculogenesis/angiogenesis
components for cell signalling (Tie2, eNOS, Ephrins,
TGFβ) and cell adhesion (adherens, tight and gap junc-
tions, cell adhesion molecules, and collagens). This
strongly indicates OECs possess intrinsic angiogenic
properties, making them an attractive EPC sub-type to be
tested for therapeutic angiogenesis.
Despite exponential growth of EPC literature, the pri-
mary origin of OECs is still uncertain. The first report
confronting this issue affirms that while circulating
endothelial cells are derived from the vessel wall, OECs
arise from bone marrow-derived circulating angioblasts
[31]. Later, the existence of a 'vasculogenic zone' in the
wall of adult human blood vessels that contains EPCs has
also been suggested [33], and a complete hierarchy of
endothelial progenitor cells including OEC-like cells were
isolated from vessel wall-derived cultures [34]. There is
even a hypothesis that OECs are 'culture artifacts' arising
from in vitro conditions [7]. Finding the in vivo counter-
part for the OECs will resolve this argument, however
such a discovery remains challenging due to the rarity of
OECs in peripheral blood. Moreover, the lack of a marker
combination that uniquely identifies OECs further
underscores the timeliness of the current study. The
molecular profile for OECs presented in this investigation
could ultimately help improve approaches for OECs iso-
lation efficiency from blood or bone marrow.
An important question has emerged around whether
adult PB, foetal CB or bone marrow offer the best source
for EPC isolation. Many reports recognize the advantages
of using CB for greater OEC isolation efficiency in com-
parison to PB [23], better ex-vivo cell number expansion,
and even longer stability of vascular networks formed in
vivo [35,36]. The current study has found that gene
expression profile of PB-derived OECs more closely
resembles that of mature endothelial cells than those cells
derived from CB. Our transcriptomic evaluation also
revealed that expression levels of progenitor markers
such as CD133, CD34, and C-Kit were higher in CB-
derived OECs than in their PB counterparts indicating an
apparent cell immaturity which is consistent with their
more primitive developmental stage and higher prolifera-
tive capacity [24]. By contrast, PB-derived OECs demon-
Figure 6 Ultrastructure analysis identifies typical endothelial fea-
tures in OECs. Representative images of eEPCs (A) and OECs (B) by 
transmission electron microscopy. White arrows indicate lysosome-like 
structures. Ultrastructural features recognized as adherens junctions 
indicated by black arrowheads (C), and abundant caveolae (D) in the 
plasma membrane were only present in OECs. Caveolae display two 
distinct morphologies, single pits (D) and clusters (E).
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may be indicative of a relative advantage when forming
tight junctions with resident endothelium.
Conclusions
Using genome-wide transcriptional profiling, we have
precisely characterized the molecular fingerprint of two
distinct EPCs. Furthermore, these progenitor transcrip-
tomes were rigorously compared to mature endothelial
cells and monocytes to elucidate on their phenotypic
nature, results from this transcriptome assessment were
strengthened and confirmed by proteomics and ultra-
structure studies. The finding that the molecular finger-
print of OECs corresponds to an endothelial phenotype,
while eEPCs are similar to monocytes should inform
future studies using these cells to promote revasculariza-
tion of ischaemic tissues.
Many clinical trials using EPCs have yielded inconsis-
tent outcomes in terms of therapeutic benefit, most of
them using very heterogeneous populations of cells. Our
results indicate that OECs might be an attractive cell can-
didate for inducing therapeutic angiogenesis, as their
transcript fingerprint, protein profile and ultrastructure
clearly indicates they are fully committed to an endothe-
lial phenotype. Our findings also suggest that eEPCs
should be used with caution and consideration of the
pathology they will treat. If injected into a pro-inflamma-
tory microenvironment, it is possible they could exacer-
bate pre-existing pathology because of their monocytic
nature.
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